1. Home
  2. FTHY vs ALT Comparison

FTHY vs ALT Comparison

Compare FTHY & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FTHY
  • ALT
  • Stock Information
  • Founded
  • FTHY 2020
  • ALT 1997
  • Country
  • FTHY United States
  • ALT United States
  • Employees
  • FTHY N/A
  • ALT N/A
  • Industry
  • FTHY Investment Managers
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • FTHY Finance
  • ALT Health Care
  • Exchange
  • FTHY Nasdaq
  • ALT Nasdaq
  • Market Cap
  • FTHY 500.1M
  • ALT 472.3M
  • IPO Year
  • FTHY N/A
  • ALT N/A
  • Fundamental
  • Price
  • FTHY $13.79
  • ALT $4.55
  • Analyst Decision
  • FTHY
  • ALT Strong Buy
  • Analyst Count
  • FTHY 0
  • ALT 8
  • Target Price
  • FTHY N/A
  • ALT $21.00
  • AVG Volume (30 Days)
  • FTHY 176.7K
  • ALT 2.2M
  • Earning Date
  • FTHY 01-01-0001
  • ALT 05-08-2025
  • Dividend Yield
  • FTHY 10.93%
  • ALT N/A
  • EPS Growth
  • FTHY N/A
  • ALT N/A
  • EPS
  • FTHY N/A
  • ALT N/A
  • Revenue
  • FTHY N/A
  • ALT $20,000.00
  • Revenue This Year
  • FTHY N/A
  • ALT N/A
  • Revenue Next Year
  • FTHY N/A
  • ALT N/A
  • P/E Ratio
  • FTHY N/A
  • ALT N/A
  • Revenue Growth
  • FTHY N/A
  • ALT N/A
  • 52 Week Low
  • FTHY $12.66
  • ALT $3.55
  • 52 Week High
  • FTHY $14.74
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • FTHY 43.00
  • ALT 43.21
  • Support Level
  • FTHY $13.49
  • ALT $4.32
  • Resistance Level
  • FTHY $13.99
  • ALT $4.75
  • Average True Range (ATR)
  • FTHY 0.35
  • ALT 0.38
  • MACD
  • FTHY 0.00
  • ALT 0.05
  • Stochastic Oscillator
  • FTHY 58.21
  • ALT 63.22

About FTHY First Trust High Yield Opportunities 2027 Term Fund

FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: